2135871-21-3

Basic information

• Product Name: phenyl (5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate
• CAS NO: 2135871-21-3
• Molecular Weight: 435.433
• Mol File: 2135871-21-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: phenyl (5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl (5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate(2135871-21-3)
• EPA Substance Registry System: phenyl (5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate(2135871-21-3)

Safety Data

• Hazardous Substances Data: 2135871-21-3(Hazardous Substances Data)

Usage

General Description

Phenyl (5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate is a chemical compound that belongs to the class of pyrazolo[1,5-a]pyrimidines. It contains a phenyl group attached to a carbamate functional group, with a pyrrolidinyl and difluorophenyl substituent. phenyl (5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate displays biological activity and has potential applications in medicinal chemistry as a target for drug discovery and development. Its unique structure and composition make it a promising candidate for further research and investigation in the field of pharmaceuticals and chemical biology.

Upstream product

• 1224944-43-7 sodium pyrazolo[1,5-a] pyrimidin-5-olate 
• 1919868-75-9 3-nitropyrazolo[1,5-a]pyrimidin-5(4H)-one 
• 1363380-51-1 5-chloro-3-nitropyrazolo[1,5-a]pyrimidine 
• 399-94-0 2-bromo-1,4-difluorobenzene 
• 1443623-92-4 5-(2,5-difluorophenyl)-3,4-dihydro-2H-pyrrole 
• 1919868-77-1 (R)-2-(2,5-difluorophenyl)-pyrrolidine (R)-2-hydroxy-succinate 
• 1223404-90-7 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-nitropyrazolo[1,5-a]pyrimidine 
• 1885-14-9 phenyl chloroformate 
• 2646-90-4 2,5-difluorobenzaldehyde 
• 1218935-60-4 (2R)-2-(2,5-difluorophenyl)pyrrolidine hydrochloride 
• 1218935-58-0 (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate 
• 899819-34-2 (2,5-difluorophenyl)magnesium bromide 
• 29274-24-6 5-chloropyrazolo[1,5-a]pyrimidine 
• 29274-22-4 4H,5H-pyrazolo[1,5-a]pyrimidine-5-one 

Relevant articles and documents

Substituted pyrazolo [1,a] pyrimidine compounds and uses thereof

The invention discloses a substituted pyrazolo [1,a] pyrimidine compound and application thereof. The compound of the formula I disclosed by the invention has a pyrazolo [1, a] pyrimidine series structure, has good inhibition effect on the original myosin

Synthesis method of Larotrectinib intermediate and Larotrectinib

The invention discloses a synthesis method of Larotrectinib and a Larotrectinib intermediate. N-Boc pyrrolidone and 2,5-difluorophenyl magnesium bromide serve as raw materials, an intermediate A-1 isprepared, the intermediate A-1 is subjected to chiral catalysis hydrogenation, cyclization or first cyclization and afterwards chiral catalysis hydrogenation to obtain a chiral pyrrodlidine intermediate A-4, the intermediate A-4 and an intermediate B-3 are condensed to obtain an intermediate AB-1, the intermediate AB-1 is reduced to obtain an intermediate AB-2, the AB-2 is acylated to obtain an intermediate AB-3, and the AB-3 is subjected to a substitution reaction to obtain the target product Larotrectinib (AB-4). The intermediate A-4 with a high yield and high chiral purity is obtained through a chiral catalysis method, the B-3 with a high yield is obtained through a solvent-free one-pot method, and the Larotrectinib (AB-4) with a high yield and high purity is obtained. According to themethod, the reaction condition can also be applied to large-scale preparation, the method is suitable for industrial production, and therefore, the method has high practical values and social and economic benefits.

METHODS OF TREATING PEDIATRIC CANCERS

A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrro